Michael A Davies

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2862910/publications.pdf

Version: 2024-02-01

199	27,241	13099	6654
papers	citations	68 h-index	156 g-index

212	212	212	32488
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Gut microbiome modulates response to antiâ€“PD-1 immunotherapy in melanoma patients. Science, 2018, 359, 97-103.	12.6	3,126
2	A Landscape of Driver Mutations in Melanoma. Cell, 2012, 150, 251-263.	28.9	2,247
3	B cells and tertiary lymphoid structures promote immunotherapy response. Nature, 2020, 577, 549-555.	27.8	1,421
4	Loss of PTEN Promotes Resistance to T Cellâ€“Mediated Immunotherapy. Cancer Discovery, 2016, 6, 202-216.	9.4	1,158
5	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. New England Journal of Medicine, 2019, 381, 626-636.	27.0	909
6	Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2012, 13, 1087-1095.	10.7	841
7	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discovery, 2016, 6, 827-837.	9.4	785
8	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Science Translational Medicine, 2017, 9, .	12.4	689
9	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nature Medicine, 2018, 24, 1649-1654.	30.7	592
10	NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer, 2012, 118, 4014-4023.	4.1	589
11	Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncology, The, 2017, 18, 863-873.	10.7	561
12	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Annals of Oncology, 2017, 28, 1631-1639.	1.2	549
13	Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncology, The, 2018, 19, 310-322.	10.7	486
14	Prognostic factors for survival in melanoma patients with brain metastases. Cancer, 2011, 117, 1687-1696.	4.1	433
15	Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metabolism, 2018, 27, 977-987.e4.	16.2	398
16	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science, 2021, 374, 1632-1640.	12.6	369
17	Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients. Clinical Cancer Research, 2012, 18, 6758-6770.	7.0	345
18	BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice. Clinical Cancer Research, 2013, 19, 393-403.	7.0	336

#	Article	IF	Citations
19	The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene, 1999, 18, 7034-7045.	5.9	288
20	Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma. Clinical Cancer Research, 2012, 18, 5329-5340.	7.0	266
21	Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncology, The, 2016, 17, 1743-1754.	10.7	266
22	A novel AKT3 mutation in melanoma tumours and cell lines. British Journal of Cancer, 2008, 99, 1265-1268.	6.4	237
23	Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncology, The, 2018, 19, 181-193.	10.7	233
24	Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discovery, 2019, 9, 628-645.	9.4	231
25	Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf-Mutant Human Cutaneous Melanoma Cells. Cancer Research, 2010, 70, 8736-8747.	0.9	222
26	Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clinical Cancer Research, 2009, 15, 7538-7546.	7.0	221
27	Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. Journal of Clinical Investigation, 2016, 126, 1834-1856.	8.2	219
28	Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nature Medicine, 2021, 27, 301-309.	30.7	218
29	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nature Medicine, 2021, 27, 1432-1441.	30.7	216
30	Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Research, 1999, 59, 2551-6.	0.9	205
31	The Role of the PI3K-AKT Pathway in Melanoma. Cancer Journal (Sudbury, Mass), 2012, 18, 142-147.	2.0	197
32	Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. Cancer Cell, 2017, 31, 225-239.	16.8	190
33	Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target. Clinical Cancer Research, 2014, 20, 5537-5546.	7.0	169
34	A Decision Support Framework for Genomically Informed Investigational Cancer Therapy. Journal of the National Cancer Institute, 2015, 107, .	6.3	168
35	Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. , 2019, 7, 319.		164
36	Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1Î± and Oxidative Phosphorylation in Melanoma. Cancer Research, 2014, 74, 7037-7047.	0.9	161

#	Article	IF	Citations
37	Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. European Journal of Cancer, 2017, 82, 45-55.	2.8	160
38	Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Research, 1998, 58, 5285-90.	0.9	160
39	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncology, The, 2019, 20, e378-e389.	10.7	155
40	Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications. Pigment Cell and Melanoma Research, 2018, 31, 11-30.	3.3	149
41	Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB/C Melanoma Patients with BRAFV600 Mutations. Clinical Cancer Research, 2014, 20, 5527-5536.	7.0	145
42	Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition. Cancer Discovery, 2020, 10, 1352-1373.	9.4	145
43	Beyond BRAF V600 : Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. Journal of Investigative Dermatology, 2015, 135, 508-515.	0.7	138
44	Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Annals of Oncology, 2018, 29, 1861-1868.	1.2	135
45	BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma. Cancer Immunology Research, 2015, 3, 602-609.	3.4	133
46	Analysis of the genome to personalize therapy for melanoma. Oncogene, 2010, 29, 5545-5555.	5.9	125
47	AKT1 Activation Promotes Development of Melanoma Metastases. Cell Reports, 2015, 13, 898-905.	6.4	124
48	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. Npj Genomic Medicine, 2017, 2, .	3.8	120
49	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nature Genetics, 2021, 53, 86-99.	21.4	118
50	A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Reports, 2017, 21, 1953-1967.	6.4	117
51	Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell, 2022, 40, 509-523.e6.	16.8	115
52	Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. , 2017, 5, 8.		111
53	Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nature Communications, 2017, 8, 607.	12.8	109
54	Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN. Oncogene, 2001, 20, 6669-6678.	5.9	107

#	Article	IF	Citations
55	Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. Nature Communications, 2021, 12, 346.	12.8	107
56	mTORC1 Activation Blocks BrafV600E-Induced Growth Arrest but Is Insufficient for Melanoma Formation. Cancer Cell, 2015, 27, 41-56.	16.8	106
57	Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Medicine, 2016, 14, 168.	5.5	106
58	Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell and Melanoma Research, 2016, 29, 627-642.	3.3	102
59	Role and therapeutic potential of PI3Kâ€mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell and Melanoma Research, 2012, 25, 248-258.	3.3	98
60	MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. Oncogene, 2000, 19, 5406-5412.	5.9	94
61	Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene. Molecular Cell, 2017, 68, 731-744.e9.	9.7	90
62	Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clinical Cancer Research, 2018, 24, 4416-4428.	7.0	89
63	Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer, 2013, 119, 3821-3829.	4.1	87
64	Targeted therapy for melanoma: rational combinatorial approaches. Oncogene, 2014, 33, 1-9.	5.9	85
65	Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors. Clinical Chemistry, 2015, 61, 544-553.	3.2	85
66	Regulation of PRMT5â€“MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 17990-18000.	7.1	81
67	Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma. Clinical Cancer Research, 2013, 19, 5310-5319.	7.0	78
68	Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma Progression. Cell Reports, 2017, 19, 875-889.	6.4	78
69	The state of melanoma: challenges and opportunities. Pigment Cell and Melanoma Research, 2016, 29, 404-416.	3.3	77
70	ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties. Molecular Cancer Research, 2018, 16, 1724-1736.	3.4	74
71	The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. Clinical Cancer Research, 2018, 24, 3366-3376.	7.0	73
72	Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. Cell Reports, 2017, 21, 1936-1952.	6.4	72

#	Article	IF	Citations
73	Emerging insights into resistance to BRAF inhibitors in melanoma. Biochemical Pharmacology, 2014, 87, 381-389.	4.4	70
74	Hotspot Mutation Panel Testing Reveals Clonal Evolution in a Study of 265 Paired Primary and Metastatic Tumors. Clinical Cancer Research, 2015, 21, 2644-2651.	7.0	70
75	<scp>RAC</scp>1 P29S regulates <scp>PD</scp>â€L1 expression in melanoma. Pigment Cell and Melanoma Research, 2015, 28, 590-598.	3.3	69
76	Nextâ€generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma. Journal of Pathology, 2016, 240, 84-95.	4.5	63
77	In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2â€“CDK4/6 Targeting and mTORâ€“S6 Resistance Mechanisms. Cancer Discovery, 2018, 8, 568-581.	9.4	62
78	Dissecting the treatment-naive ecosystem of human melanoma brain metastasis. Cell, 2022, 185, 2591-2608.e30.	28.9	62
79	New Strategies in Melanoma: Molecular Testing in Advanced Disease. Clinical Cancer Research, 2012, 18, 1195-1200.	7.0	61
80	A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma. Clinical Cancer Research, 2019, 25, 6429-6442.	7.0	61
81	Phosphatidylinositol-3-Kinase as a Therapeutic Target in Melanoma. Clinical Cancer Research, 2009, 15, 3029-3036.	7.0	59
82	Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiotherapy and Oncology, 2017, 125, 80-88.	0.6	58
83	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Nature Communications, 2021, 12, 5086.	12.8	58
84	Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma. Clinical Cancer Research, 2012, 18, 1120-1128.	7.0	57
85	Evaluating Circulating Tumor DNA From the Cerebrospinal Fluid of Patients With Melanoma and Leptomeningeal Disease. Journal of Neuropathology and Experimental Neurology, 2018, 77, 628-635.	1.7	57
86	Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. Lancet Oncology, The, 2021, 22, 370-380.	10.7	57
87	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. OncoImmunology, 2016, 5, e1136044.	4.6	55
88	Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma. Molecular Cancer Therapeutics, 2017, 16, 516-528.	4.1	55
89	A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discovery, 2018, 8, 556-567.	9.4	55
90	Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature, 2022, 606, 797-803.	27.8	54

#	Article	IF	Citations
91	Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity. , 2020, 8, e000289.		51
92	PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets. Cancer Research, 2015, 75, 1399-1412.	0.9	50
93	Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. OncoImmunology, 2017, 6, e1361097.	4.6	50
94	Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. Cancer Discovery, 2017, 7, 832-851.	9.4	49
95	Regulation, Role, and Targeting of Akt in Cancer. Journal of Clinical Oncology, 2011, 29, 4715-4717.	1.6	48
96	Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases. Clinical Cancer Research, 2017, 23, 2093-2104.	7.0	48
97	Erythema nodosumâ€like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapyâ€"Report of 2 patients. Journal of Cutaneous Pathology, 2017, 44, 1080-1086.	1.3	48
98	AKT1E17K Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis. Molecular Cancer Research, 2019, 17, 1787-1800.	3.4	46
99	Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor. Cancer Research, 2014, 74, 4122-4132.	0.9	45
100	Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open, 2018, 3, e000283.	4.5	45
101	High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiotherapy and Oncology, 2021, 162, 60-67.	0.6	45
102	Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Human Pathology, 2015, 46, 1101-1110.	2.0	43
103	Development of a robust classifier for quality control of reverse-phase protein arrays. Bioinformatics, 2015, 31, 912-918.	4.1	43
104	Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series. Cancer, 2020, 126, 523-530.	4.1	43
105	Clinical Models to Define Response and Survival With Antiâ€"PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. Journal of Clinical Oncology, 2022, 40, 1068-1080.	1.6	43
106	FOXD3 Regulates VISTA Expression in Melanoma. Cell Reports, 2020, 30, 510-524.e6.	6.4	42
107	Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. Clinical Cancer Research, 2020, 26, 1886-1895.	7.0	42
108	Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitorâ€"Refractory Metastatic Melanoma. JAMA Oncology, 2016, 2, 1056.	7.1	41

#	Article	IF	Citations
109	Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes. Journal of Investigative Dermatology, 2017, 137, 1792-1795.	0.7	40
110	Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines. Cancer Cell, 2020, 38, 829-843.e4.	16.8	40
111	Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma. Clinical Cancer Research, 2016, 22, 3016-3024.	7.0	39
112	Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. Neuro-Oncology, 2022, 24, 1613-1646.	1.2	39
113	Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. Cancer Immunology Research, 2020, 8, 1365-1380.	3.4	37
114	Clinicopathological features and clinical outcomes associated with TP53 and BRAF^N^{ona€}^V⁶⁰⁰ mutations in cutaneous melanoma patients. Cancer, 2017, 123, 1372-1381.	4.1	36
115	Targeting USP7 Identifies a Metastasis-Competent State within Bone Marrowâ€"Resident Melanoma CTCs. Cancer Research, 2018, 78, 5349-5362.	0.9	36
116	Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions. Pigment Cell and Melanoma Research, 2020, 33, 527-541.	3.3	36
117	Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3KÎ² Inhibition in PTEN Loss Melanoma. Clinical Cancer Research, 2019, 25, 6406-6416.	7.0	35
118	Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature Communications, 2022, 13, 1970.	12.8	34
119	Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-ÎºB Pathway in Melanoma. Clinical Cancer Research, 2017, 23, 4831-4842.	7.0	33
120	Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). Journal of Neuro-Oncology, 2019, 142, 499-509.	2.9	33
121	Tilsotolimod with Ipilimumab Drives Tumor Responses in Antiâ€"PD-1 Refractory Melanoma. Cancer Discovery, 2021, 11, 1996-2013.	9.4	32
122	Profiles of brain metastases: Prioritization of therapeutic targets. International Journal of Cancer, 2018, 143, 3019-3026.	5.1	31
123	Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. Pigment Cell and Melanoma Research, 2019, 32, 458-469.	3.3	31
124	Multi-omic molecular profiling reveals potentially targetable abnormalities shared across multiple histologies of brain metastasis. Acta Neuropathologica, 2021, 141, 303-321.	7.7	30
125	Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report. Cancer Immunology Research, 2015, 3, 1201-1206.	3.4	29
126	Firstâ€inâ€human trial of the PI3KÎ²â€selective inhibitor SAR260301 in patients with advanced solid tumors. Cancer, 2018, 124, 315-324.	4.1	29

#	Article	IF	Citations
127	SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex. Cancer Research, 2015, 75, 5211-5218.	0.9	28
128	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. European Journal of Cancer, 2022, 162, 22-33.	2.8	28
129	Point mutations of protein kinases and individualised cancer therapy. Expert Opinion on Pharmacotherapy, 2006, 7, 2243-2261.	1.8	27
130	Upregulation of cell surface GD3 ganglioside phenotype is associated with human melanoma brain metastasis. Molecular Oncology, 2020, 14, 1760-1778.	4.6	27
131	Targeted Therapy for Melanoma: A Primer. Surgical Oncology Clinics of North America, 2011, 20, 165-180.	1.5	25
132	An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma. Cancer Research, 2016, 76, 5455-5466.	0.9	24
133	Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. , 2021, 9, e002531.		24
134	Targeted Therapy Resistance Mechanisms and Therapeutic Implications in Melanoma. Hematology/Oncology Clinics of North America, 2014, 28, 523-536.	2.2	23
135	Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition. Journal of Investigative Dermatology, 2020, 140, 2242-2252.e7.	0.7	23
136	Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. Journal of Clinical Oncology, 2020, 38, 1429-1441.	1.6	23
137	A Phase I Multi-Institutional Study of Systemic Sorafenib in Conjunction with Regional Melphalan for In-Transit Melanoma of the Extremity. Annals of Surgical Oncology, 2012, 19, 3896-3905.	1.5	22
138	Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo. Molecular Cancer Therapeutics, 2018, 17, 84-95.	4.1	22
139	Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma. Molecular Cancer Therapeutics, 2020, 19, 1719-1726.	4.1	22
140	Differential Effects of Phosphatidylinositol-3/Akt-Kinase Inhibition on Apoptotic Sensitization to Cytokines in LNCaP and PC-3 Prostate Cancer Cells. Journal of Interferon and Cytokine Research, 2001, 21, 313-322.	1.2	21
141	Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Oncogene, 2002, 21, 2357-2364.	5.9	21
142	Somatic Mutations in MAP3K5 Attenuate Its Proapoptotic Function in Melanoma through Increased Binding to Thioredoxin. Journal of Investigative Dermatology, 2014, 134, 452-460.	0.7	20
143	Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [18F]FAZA PET In Vivo. Cells, 2019, 8, 1487.	4.1	20
144	Efficacy and Safety of Trametinib in <scp>Non-V600 BRAF </scp> Mutant Melanoma: A Phase II Study. Oncologist, 2021, 26, 731-e1498.	3.7	20

#	Article	IF	Citations
145	Gas6/Axl is the sensor of arginine-auxotrophic response in targeted chemotherapy with arginine-depleting agents. Oncogene, 2016, 35, 1632-1642.	5.9	19
146	Biological Validation of RNA Sequencing Data From Formalin-Fixed Paraffin-Embedded Primary Melanomas. JCO Precision Oncology, 2018, 2018, 1-19.	3.0	19
147	ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. Cancer Research, 2018, 78, 5680-5693.	0.9	19
148	Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. Modern Pathology, 2020, 33, 496-513.	5.5	19
149	ErbB3â€“ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas. Cancer Research, 2015, 75, 3554-3567.	0.9	18
150	Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. Annals of Oncology, 2020, 31, 1569-1579.	1.2	18
151	Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition. Cancer Immunology Research, 2022, 10, 996-1012.	3.4	18
152	Melanoma brain metastases harboring BRAF V600K or NRAS mutations are associated with an increased local failure rate following conventional therapy. Journal of Neuro-Oncology, 2018, 137, 67-75.	2.9	17
153	Genotyping of cutaneous melanoma. Chinese Clinical Oncology, 2014, 3, 27.	1.2	17
154	Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. , 2021, 9, e002449.		16
155	Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. Scientific Reports, 2016, 6, 19649.	3.3	15
156	Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma. British Journal of Cancer, 2020, 122, 789-800.	6.4	15
157	Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nature Communications, 2020, 11, 1839.	12.8	15
158	Targeted Therapy Given after Antiâ€“PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity. Cancer Immunology Research, 2021, 9, 554-567.	3.4	15
159	The efficacy of antiâ€programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma. Cancer Medicine, 2021, 10, 2293-2299.	2.8	15
160	In Vivo ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma. Molecular Cancer Therapeutics, 2019, 18, 1637-1648.	4.1	14
161	LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade. Journal of Clinical Investigation, 2022, 132, .	8.2	14
162	MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRASÂMelanoma. Journal of Investigative Dermatology, 2016, 136, 453-463.	0.7	13

#	Article	IF	Citations
163	High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens. Scientific Reports, 2021, 11, 9043.	3.3	13
164	Clinical, molecular, metabolic, and immune features associated with oxidative phosphorylation in melanoma brain metastases. Neuro-Oncology Advances, 2021, 3, vdaa177.	0.7	12
165	Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with antiâ€CTLA4 and antiâ€PD1 combination immunotherapy: Incidence, management, and clinical benefit. Cancer, 2022, 128, 975-983.	4.1	12
166	Targeted Therapy for Brain Metastases. Advances in Pharmacology, 2012, 65, 109-142.	2.0	11
167	Use of clinical nextâ€generation sequencing to identify melanomas harboring <scp>SMARCB1</scp> mutations. Journal of Cutaneous Pathology, 2015, 42, 308-317.	1.3	11
168	Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma. Clinical Cancer Research, 2018, 24, 4119-4125.	7.0	11
169	Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. Cancer Medicine, 2020, 9, 8650-8661.	2.8	11
170	Converting biology into clinical benefit: lessons learned from BRAF inhibitors. Melanoma Management, 2015, 2, 241-254.	0.5	10
171	Assessment of Compliance With Texas Legislation Banning Indoor UV Tanning by Minors. JAMA Dermatology, 2017, 153, 228.	4.1	10
172	Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma. Cell Death and Disease, 2020, 11, 882.	6.3	10
173	Is It Safe to Stop Antiâ€“PD-1 Immunotherapy in Patients With Metastatic Melanoma Who Achieve a Complete Response?. Journal of Clinical Oncology, 2020, 38, 1645-1647.	1.6	10
174	iNOS Associates With Poor Survival in Melanoma: A Role for Nitric Oxide in the PI3K-AKT Pathway Stimulation and PTEN S-Nitrosylation. Frontiers in Oncology, 2021, 11, 631766.	2.8	10
175	COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600â€“mutant (mut) melanoma brain metastases (MBM).. Journal of Clinical Oncology, 2017, 35, 9506-9506.	1.6	10
176	Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with antiâ€“PDâ€1 in patients with metastatic melanoma. Cancer, 2019, 125, 4193-4202.	4.1	9
177	Multi-modal molecular programs regulate melanoma cell state. Nature Communications, 2022, 13, .	12.8	9
178	Sex as a predictor of response to cancer immunotherapy. Lancet Oncology, The, 2018, 19, e376.	10.7	8
179	Modern Management of Central Nervous System Metastases in the Era of Targeted Therapy and Immune Oncology. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e59-e69.	3.8	8
180	Moving treatments earlier to move further forwards. Nature Reviews Clinical Oncology, 2018, 15, 75-76.	27.6	7

#	Article	IF	Citations
181	Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era. Annals of Surgical Oncology, 2021, 28, 3480-3489.	1.5	7
182	Identification of MicroRNAâ€“mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. Cancers, 2021, 13, 5301.	3.7	7
183	Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf -mutated melanoma. OncoImmunology, 2021, 10, 1992880.	4.6	7
184	PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery. NAR Cancer, 2022, 4, zcac014.	3.1	7
185	Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: a case report. Immunotherapy, 2020, 12, 1213-1219.	2.0	6
186	IMCT-07THERAPEUTIC OUTCOMES OF INTRATHECAL INTERLEUKIN-2 IN METASTATIC MELANOMA PATIENTS WITH LEPTOMENINGEAL DISEASE (LMD). Neuro-Oncology, 2015, 17, v108.3-v108.	1.2	5
187	How Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments?. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 787-792.	4.9	4
188	Estrogen returns to the stage in melanoma. Pigment Cell and Melanoma Research, 2018, 31, 554-555.	3.3	4
189	Finding the Right Balance of BRAF Inhibition in Melanoma. Cancer Discovery, 2014, 4, 510-512.	9.4	3
190	Body-mass index and metastatic melanoma outcomes â€“ Authors' reply. Lancet Oncology, The, 2018, 19, e227-e228.	10.7	3
191	Primary medical therapy for BRAFV600E-mutant melanoma brain metastasesâ€”is this good enough? â€“ Authors' reply. Lancet Oncology, The, 2017, 18, e509.	10.7	3
192	Targeted therapy strategies for melanoma brain metastasis. Neuro-Oncology Advances, 2021, 3, v75-v85.	0.7	3
193	Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. Clinical Cancer Research, 2022, 28, 1911-1924.	7.0	3
194	Case Report: Sarcoidosis mimicking head and neck cancer progression. F1000Research, 2019, 8, 215.	1.6	2
195	Reâ€thinking therapeutic development for CNS metastatic disease. Experimental Dermatology, 2021, , .	2.9	1
196	Role and complexity of nextâ€generation sequencing in melanoma. Cancer Cytopathology, 2015, 123, 329-330.	2.4	0
197	BRAFin early stage melanoma: rationale for testing and treatment?. British Journal of Dermatology, 2015, 173, 9-10.	1.5	0
198	Reply to A. Shinde et al. Journal of Clinical Oncology, 2019, 37, 1031-1032.	1.6	0

#	Article	IF	Citations
199	EXTH-06. INTEGRATED MOLECULAR PROFILING REVEALS TARGETABLE MOLECULAR ABNORMALITIES SHARED ACROSS MULTIPLE HISTOLOGIES OF BRAIN METASTASIS. Neuro-Oncology, 2020, 22, ii87-ii88.	1.2	0